Brought to you by 
Wave Life Sciences raises $66mm in Series B offering
29 Sep 2015
Executive Summary
Genetic medicine company Wave Life Sciences raised $66mm in an oversubscribed Series B preferred stock financing. The funding was led by Foresite Capital with participation from Fidelity Management, New Leaf Venture Partners, Redmile Group, Jennison Associates, Comorant Asset Management, RA Capital Management, Kagoshima Shinsangyo Sosei Investment, and private investment funds advised by Clough Capital Partners LP. Leerink Partners was the placement agent. Wave will use the proceeds for its chemistry platform and to further develop its pipeline of stereopure nucleic acid therapeutics for Huntington's disease and Duchenne muscular dystrophy.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Antisense, Oligonucleotides
- Drug Discovery Tools
- Gene Therapy, Cell Therapy
- Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Wave Life Sciences raises $66mm in Series B offering
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice